Abstract
e17547Background: Adding to bevacizumab to chemotherapy improves progression-free survival for platinum-resistant ovarian cancer. This study evaluates effectiveness of 2nd-line or 3rd-line bevacizu...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
